Isotretinoin - Patagonia Pharmaceuticals

Drug Profile

Isotretinoin - Patagonia Pharmaceuticals

Alternative Names: PAT-001

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Patagonia Pharmaceuticals
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital ichthyosiform erythroderma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Congenital ichthyosiform erythroderma

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Congenital ichthyosiform erythroderma (In adolescents, In adults) in USA (Topical) (NCT02864082)
  • 16 Aug 2016 Chemical structure information added
  • 08 Aug 2016 Patagonia Pharmaceuticals plans a phase II trial for Congenital ichthyosiform erythroderma (In adolescents, In adults) in USA (Topical) (NCT02864082; Patagonia Pharmaceuticals pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top